<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30176513</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>20</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>20</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-1967</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>70</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer treatment reviews</Title>                <ISOAbbreviation>Cancer Treat. Rev.</ISOAbbreviation>            </Journal>            <ArticleTitle>Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy.</ArticleTitle>            <Pagination>                <MedlinePgn>138-143</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0305-7372(18)30144-0</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ctrv.2018.08.009</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hormone receptor positive breast cancer is characterized by a prolonged risk of recurrence. Extended adjuvant endocrine therapy improves disease-free survival (DFS), but no effect on overall survival has been observed. This may be explained by changes in the relative contribution of local, regional and distant recurrences as well as non-breast cancer death to DFS events over time.</AbstractText>                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We reviewed sequential reports of large, randomized, adjuvant endocrine therapy trials extracting the number and types of recurrences defining DFS events at each point over follow-up. Meta-regression was performed to explore the relative contribution of contralateral, loco-regional and distant recurrences as well as non-breast cancer death to DFS over time.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Analysis included 17 reports of 6 trials reporting outcomes between 28 and 120 months of follow-up. Over time, there was increasing contribution of contralateral breast cancer (5% of events at 20 months to 12% at 120 months; β = 0.663, p = 0.004) and non-breast cancer death (20% of events at 20 months to 32% at 120 months; β = 0.581, p = 0.01). There was a non-significant reduction in the contribution of distant recurrence (57% of events at 20 months to 45% at 120 months; β = -0.397, p = 0.11), but no change in loco-regional recurrence (18% of events at 20 months to 11% at 120 months; β = -0.301, p = 0.30).</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">With increasing follow-up, DFS events are increasing defined by contralateral recurrence and non-breast cancer deaths with a trend for fewer distant recurrences. This may explain the limited association between DFS and overall survival with extended adjuvant endocrine therapy.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Algorashi</LastName>                    <ForeName>Ibrahim</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada; King Fahad Medical City, Riyadh, Saudi Arabia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Goldvaser</LastName>                    <ForeName>Hadar</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada; Davidoff Cancer Centre, Beilinson Hospital and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ribnikar</LastName>                    <ForeName>Domen</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cescon</LastName>                    <ForeName>David W</ForeName>                    <Initials>DW</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Amir</LastName>                    <ForeName>Eitan</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada. Electronic address: eitan.amir@uhn.ca.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>24</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Cancer Treat Rev</MedlineTA>            <NlmUniqueID>7502030</NlmUniqueID>            <ISSNLinking>0305-7372</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D047072">Aromatase Inhibitors</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047072" MajorTopicYN="N">Aromatase Inhibitors</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Adjuvant endocrine therapy</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Disease free survival</Keyword>            <Keyword MajorTopicYN="N">Overall survival</Keyword>            <Keyword MajorTopicYN="N">Sites of recurrence</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30176513</ArticleId>            <ArticleId IdType="pii">S0305-7372(18)30144-0</ArticleId>            <ArticleId IdType="doi">10.1016/j.ctrv.2018.08.009</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>